Publication | Closed Access

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

OncologyClinical TranslationOriginator InfliximabClinical TrialsClinical EvidenceClinical ReviewTreatment OptionPharmacotherapyNon-inferiority TrialMedicineMaintained TreatmentRadiologyHealth Sciences